The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 09, 2023

Filed:

Sep. 06, 2018
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Edgar Davidson Charles, III, Westfield, NJ (US);

Rose C. Christian, Hopewell, NJ (US);

Yi Luo, Southampton, PA (US);

Assignee:

BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/18 (2006.01); A61P 1/16 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1825 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01); G01N 33/6887 (2013.01); G01N 2333/78 (2013.01); G01N 2800/085 (2013.01);
Abstract

Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH. Also provided are methods for monitoring responsiveness of a patient having NASH to treatment with a modified FGF-21, the method comprising: determining the serum Pro-C3 level in a blood sample from the patient obtained during or after treatment, wherein: a decreased serum Pro-C3 level in the blood sample from the patient obtained during or after treatment, as compared to the serum Pro-C3 level in a blood sample from the patient obtained prior to treatment with the modified FGF-21, indicates that the patient is responsive to treatment with the modified FGF-21.


Find Patent Forward Citations

Loading…